Life Sciences Yearbook 2024 – online PDF
Please see below for a link to an online pdf of the Life Sciences Yearbook 2024. Life Sciences Yearbook 2024 complete pdf link
Life Sciences Yearbook 2024 – Editor’s letter
Welcome to the 2024 Life Sciences Yearbook from the Legal 500 and Legal Business, sponsored by Herbert Smith Freehills. This yearly publication will offer insight into the issues facing life sciences companies in the wake of Brexit, as well as interviews with leading private practice lawyers in the sector and a data-driven snapshot of the …
Continue reading “Life Sciences Yearbook 2024 – Editor’s letter”
Life Sciences Yearbook 2024: Sponsored foreword – Herbert Smith Freehills
‘Economic and geopolitical pressures continued throughout 2023, making the global business landscape a volatile one. It might even be asked whether disruption is simply the new business norm.’ Global themes in 2023 and outlook The disruption felt globally at the end of 2022 continued to impact life sciences companies and investors in 2023.
‘You’d be a brave innovator to ignore the UK’ – why patent work is booming in the post-Brexit UK life sciences market
Buzz about blockbuster drug developments, expiring patents and the launch of the European Union’s Unified Patent Court – 2023 certainly kept the life sciences sector on its toes. Against a backdrop of several of the world’s best-selling drugs nearing their patent expiration dates and the market getting to grips with the implications of the long-awaited …
Lead partner: The year the United Kingdom becomes a globally leading life sciences hub?
As part of its ambition for the United Kingdom to become a tech and science superpower by 2030, in 2023, the government announced a range of initiatives aimed at boosting investment and innovation in the life sciences sector. Innovators will have welcomed the R&D tax relief reforms whilst the Mansion House Compact (the largest UK …
Taking back control – the post-pandemic landscape for life sciences regulation
After years of delays caused by geopolitical instability and the Covid-19 pandemic, the new regulatory landscape for the life sciences industry is beginning to take shape in both the UK and the EU. As the UK pushes ahead with its post-Brexit journey of divergence, establishing itself as an innovation-friendly environment in the global life sciences …
Continue reading “Taking back control – the post-pandemic landscape for life sciences regulation”
Life Sciences perspectives: Grant Castle
Why did you decide to specialise in life sciences? I have a science background – a PhD in organic chemistry – and worked for a short time as a medicinal chemist for Glaxo. I also had an interest in the humanities at school, so law had always seemed to be an option, and life sciences …
The Legal 500 view: Healthy competition
The Legal 500’s life science and healthcare industry focus ranking was introduced three years ago to recognise firms with dedicated cross-practice teams advising high-profile clients across the sector.
Rising stars: Zina Chatzidimitriadou – ‘It is the one legal area that affects every single one of us and is, above all, human-centred’
Zina Chatzidimitriadou, senior managing associate at Sidley, on why she picked a career in life sciences law Why did you decide to specialise in life sciences law? In 2009, in my previous life as a molecular biologist at the Cancer Research UK institute, I experienced the multiple issues and complexities facing researchers and people involved …
Rising stars: Jaspreet Takhar – ‘EU regulators are preparing an avalanche of new laws that are going to have a monumental impact on pharma and medtech’
Baker McKenzie’s Jaspreet Takhar on the future of digital health solutions What made you decide to specialise in life sciences law? I specialise in advising on digital health solutions – that means advising on the regulation of health data, digital health solutions (including AI solutions, software and medical devices), as well as contracting in this …